Litcius/Paper detail

Circular RNA circ_0026359 Enhances Cisplatin Resistance in Gastric Cancer via Targeting miR‐1200/POLD4 Pathway

Zongyao Zhang, Xin Yu, Bo Zhou, Jiajia Zhang, Jiacong Chang

2020BioMed Research International42 citationsDOIOpen Access PDF

Abstract

Human gastric cancer is one of the most common malignant tumors with a poor prognosis. Cisplatin (CDDP) is a well-known first-line chemotherapeutic drug. Acquired resistance retards the clinical application of CDDP in gastric cancer. In this study, circular RNA circ_0026359 was demonstrated to be overexpressed in gastric cancer tissues/cells compared with normal gastric tissues/cells and was overexpressed in CDDP-resistant gastric cancer tissues/cells compared with CDDP-sensitive gastric cancer tissues/cells. High levels of circ_0026359 were associated with low overall survival (OS) and relapse-free survival (RFS) rates in gastric cancer patients. circ_0026359 was examined to promote CDDP resistance in gastric cancer cells. circ_0026359 directly interacted and negatively regulated miR-1200. POLD4 was a direct target of miR-1200. miR-1200/POLD4 pathway mediated the promoting role of circ_0026359 in CDDP resistance of gastric cancer. circ_0026359 could be used as a potential target for CDDP-resistant gastric cancer therapy.

Topics & Concepts

CisplatinCancerCancer researchCancer cellCircular RNADrug resistanceMedicinemicroRNAInternal medicineOncologyChemotherapyBiologyGeneMicrobiologyBiochemistryCircular RNAs in diseasesMicroRNA in disease regulationGenomics, phytochemicals, and oxidative stress
Circular RNA circ_0026359 Enhances Cisplatin Resistance in Gastric Cancer via Targeting miR‐1200/POLD4 Pathway | Litcius